sorafenib has been researched along with Mouth Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, A; Asakawa, N; Hirata, G; Kurita, A; Nishisaka, F; Ogo, N; Shishido, Y; Takagi, A; Takahashi, H; Taniguchi, K; Tsugane, M | 1 |
| Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC | 1 |
| Cho, NP; Cho, SD; Chung, TH; Jang, B; Jeong, JH; Kim, LH; Shin, JA; Won, DH; Yang, IH | 1 |
3 other study(ies) available for sorafenib and Mouth Neoplasms
| Article | Year |
|---|---|
Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Interleukin-6; Mice; Molecular Docking Simulation; Mouth Neoplasms; Oxadiazoles; Protein Multimerization; Quinolines; Signal Transduction; Sorafenib; src Homology Domains; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays | 2020 |
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Humans; Mouth Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Sorafenib; Staining and Labeling; Sulfonamides | 2017 |